BAPRAS advises patients on risk of ALCL

20th March 2015

 

A new study by the French National Cancer Institute has reported a small risk between Anaplastic Large Cell Lymphoma (ALCL) and textured breast implants. 

While ALCL is a very rare condition, we appreciate there will be patients with implants who will want to seek advice and reassurance from their GPs and surgeons. 

It is the responsibility of the operating surgeon to ensure that the patient is told verbally and in writing of the risk of ALCL before the procedure so they can make a fully informed decision before going ahead.

We advise that any women with breast implants who experience any sudden unexplained changes, lumps or swelling should speak to their GP or their surgeon urgently. However, until any further evidence is presented there is no need to remove breast implants as a matter of course. 

To help drive patient safety and standards, BAPRAS is working with the Department of Health, iCOBRA (The International Collaboration of Breast Registry Activities), implant manufacturers and providers in the development of a UK breast implant register, which is being piloted at the moment.

 

Back to list page
News and Views